Pay in 4 interest-free payments of $5.15 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
August 2025: Viking Therapeutics announced positive topline Phase II VENTURE-Oral results for VK2735 tablet, a once-daily oral dual GLP-1/GIP receptor agonist, with up to 12.2% mean weight loss after 13 weeks
Because FXR agonists are the most favorable agents, they may be fundamental drugs for combination
For patients in whom gastrointestinal side effects are contributing to a sensation of breathlessness through bloating or reflux, dietary modifications may prove beneficial
Hair thinning has also been noted in the context of significant rapid weight loss associated with GLP-1-based therapies
US$ 20.57
US$ 27.41
US$ 23.38
US$ 26.92
US$ 29.85
US$ 24.00
US$ 25.08
US$ 21.59
US$ 24.45
US$ 26.35
US$ 25.65
